Drugs / Adenosine
Adenosine
also known as
adenosin · 9-.beta.-d-ribofuranosyladenine · Adenocard · Adenocor · Adenoscan · Adenoscan(adenosine) · NSC-7652 · SR 96225
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ADENOSCAN | — | 2001-08-31 | fda.gov ↗ |
| Approved | US (FDA) | ADENOCARD | — | 1989-10-30 | fda.gov ↗ |
Trials 43
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03738943 | Feb 2019 → Jun 2021 | — | Colorado State University | Completed | No outcome recorded |
| Phase 0 | NCT00693758 | Jan 2006 → Sep 2011 | myocardial ischemia | University of Calgary | Completed | No outcome recorded |
| Phase 14 trials | ||||||
| Phase 1 | NCT02462941 | Jul 2015 → Apr 2016 | atrioventricular block | Columbia University | Completed | No outcome recorded |
| Phase 1 | NCT01690884 | Aug 2012 → Jan 2017 | coronary artery disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 1 | NCT01161121 | Jul 2010 → Apr 2013 | coronary artery disorder | St. Louis University | Completed | No outcome recorded |
| Phase 1 | NCT00179010 | Oct 2003 → Jan 2017 | ischemic disease | Vanderbilt University Medical Center | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT01123525 | Apr 2010 → Apr 2011 | intermediate coronary syndrome | University Hospital of North Norway | Completed | No outcome recorded |
| Phase 1/2 | NCT00881686 | Jun → Dec 2008 | congenital heart defects, multiple types | Xijing Hospital | Completed | No outcome recorded |
| Phase 28 trials · 2 missed | ||||||
| Phase 2 | NCT04588441 | Dec 2023 → Dec 2025 | acute respiratory distress syndrome | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT02867878 | Aug 2016 → Oct 2018 | Tako-tsubo cardiomyopathy | University Hospital of Ferrara | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02681913 | Feb 2016 → Jul 2018 | cardiomyopathy | Amphia Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01747174 | Oct 2011 → Oct 2014 | ST-elevation myocardial infarction | University Hospitals, Leicester | Completed | Missed primary |
| Phase 2 | NCT03032965 | Oct 2011 → Jul 2015 | paroxysmal atrial fibrillation | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT01593644 | Jun 2011 → Mar 2013 | ischemic disease | Adenobio N.V | Unknown | No outcome recorded |
| Phase 2 | NCT00284323 | Jan 2006 → ? | ST-elevation myocardial infarction | University Hospital, Gasthuisberg | Unknown | Missed primary |
| Phase 2 | NCT00298636 | Oct 2005 → ? | — | Xsira Pharmaceuticals | Completed | No outcome recorded |
| Phase 311 trials · 1 met primary · 1 missed | ||||||
| Phase 3 | NCT06717685 | Oct 2024 → Jan 2025 overdue | cardiac rhythm disease | Rashid Latif Medical College | Recruiting | No outcome recorded |
| Phase 3 | NCT05014061 | Jan 2023 → Jun 2025 | myocardial ischemia | Vastra Gotaland Region | Withdrawn | No outcome recorded |
| Phase 3 | NCT02350439 | Jan → Oct 2015 | coronary artery disorder | University of Patras | Completed | Met primary |
| Phase 3 | NCT01932112 | Nov 2012 → Apr 2015 | atrial fibrillation, congenital pulmonary veins anomaly | Yong Seog Oh | Completed | No outcome recorded |
| Phase 3 | NCT01313572 | Aug 2011 → Apr 2012 | coronary artery disorder | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT00990327 | Nov 2009 → Apr 2012 | coronary artery disorder | Forest Laboratories | Terminated | No outcome recorded |
| Phase 3 | NCT03231371 | Nov 2008 → Jan 2011 | — | Bryan Goldstein | Completed | No outcome recorded |
| Phase 3 | NCT00781404 | Oct 2008 → May 2012 | acute myocardial infarction | David Garcia-Dorado | Completed | Missed primary |
| Phase 3 | NCT00612521 | Aug 2007 → Aug 2008 | coronary stenosis | Ottawa Heart Institute Research Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT00944970 | Oct 2005 → Dec 2006 | coronary artery disorder | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00944294 | Feb 2004 → Apr 2006 | coronary artery disorder | Pfizer | Completed | No outcome recorded |
| Phase 46 trials | ||||||
| Phase 4 | NCT07243119 | Dec 2025 → Apr 2029 expected | systolic heart failure | Gødstrup Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT07536802 | Jun 2025 → May 2026 overdue | ST-elevation myocardial infarction, coronary artery disorder | National Institute of Cardiovascular Diseases, Pakistan | Recruiting | No outcome recorded |
| Phase 4 | NCT07554170 | May 2024 → Dec 2025 | cardiac rhythm disease | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03557385 | Jan 2019 → May 2022 | — | Duke University | Completed | No outcome recorded |
| Phase 4 | NCT03218137 | Feb 2017 → Dec 2027 expected | — | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 4 | NCT00413712 | Jan 1997 → Mar 2001 | — | Singapore General Hospital | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT04685941 | Jan 2021 → Oct 2022 | coronary microvascular disorder, myocardial infarction | Fundación EPIC | Completed | No outcome recorded |
| — | NCT03344679 | Feb 2015 → Jun 2017 | female breast carcinoma | Menoufia University | Completed | No outcome recorded |
| — | NCT01939912 | Aug 2013 → Sep 2016 | heart failure | Noblewell | Completed | No outcome recorded |
| — | NCT01590875 | May 2012 → Jun 2015 | atrial fibrillation | Medical College of Wisconsin | Completed | No outcome recorded |
| — | NCT01482169 | Mar 2012 → May 2014 | coronary artery disorder | Ochsner Health System | Completed | No outcome recorded |
| — | NCT01495481 | Jan 2012 → Jul 2014 | — | University of Pittsburgh | Completed | No outcome recorded |
| — | NCT01162824 | Jan → Apr 2011 | atherosclerosis, myocardial ischemia | St George's Healthcare NHS Trust | Unknown | No outcome recorded |
| — | NCT00859833 | Feb 2009 → Jul 2010 | obesity disorder | University of Utah | Completed | No outcome recorded |
| — | NCT00253929 | Nov 2005 → Feb 2006 | — | Radboud University Medical Center | Completed | No outcome recorded |
| — | NCT00184847 | Mar 2005 → ? | ischemic disease | Radboud University Medical Center | Suspended | No outcome recorded |
| Comparator or background therapy34 trials | ||||||
| Phase 0 | NCT04600115 Background | Mar 2017 → Mar 2027 expected | MRI defined brain infarct | University of Utah | Recruiting | No outcome recorded |
| Phase 1 | NCT04744636 Background | Apr 2017 → Sep 2018 | type 2 diabetes mellitus | Servier | Completed | No outcome recorded |
| Phase 1 | NCT00580905 Comparator | Jun 2007 → Jan 2017 | — | Vanderbilt University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT00845689 Comparator | — | liver and intrahepatic bile duct neoplasm | Ludwig-Maximilians - University of Munich | Unknown | No outcome recorded |
| Phase 2 | NCT07187895 Background | Dec 2024 → Mar 2025 | coronary artery disorder | Sinotau Pharmaceutical Group | Terminated | No outcome recorded |
| Phase 2 | NCT05885841 Background | Feb 2022 → May 2023 | coronary artery disorder | Sinotau Pharmaceutical Group | Completed | No outcome recorded |
| Phase 2 | NCT00349921 Comparator | Aug 2004 → Jan 2008 | — | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT01234870 Background | Jun 2010 → Jan 2012 | coronary atherosclerosis, myocardial ischemia | Northwestern University | Completed | No outcome recorded |
| Phase 2/3 | NCT00590070 Comparator | Jan 2008 → Jun 2011 | myocardial infarction | Catholic University of the Sacred Heart | Completed | No outcome recorded |
| Phase 3 | NCT03354273 Background | Jun 2018 → May 2022 | coronary artery disorder | GE Healthcare | Completed | Met primary |
| Phase 3 | NCT04392362 Comparator | Apr 2018 → Dec 2020 | cardiac rhythm disease | University of Pretoria | Completed | No outcome recorded |
| Phase 3 | NCT01809743 Comparator | Jan → Oct 2013 | coronary artery disorder | Lokien van Nunen | Completed | No outcome recorded |
| Phase 3 | NCT01148147 Comparator | Nov 2009 → Aug 2010 | coronary artery disorder | Azienda Ospedaliero Universitaria Maggiore della Carita | Completed | No outcome recorded |
| Phase 3 | NCT00751491 Comparator | Sep 2008 → Sep 2009 | coronary artery disorder | University of Roma La Sapienza | Unknown | No outcome recorded |
| Phase 3 | NCT00208312 Comparator | Apr 2004 → Jun 2005 | coronary artery disorder | Gilead Sciences | Completed | Met primary |
| Phase 3 | NCT00208299 Comparator | Oct 2003 → Aug 2006 | coronary artery disorder | Gilead Sciences | Completed | No outcome recorded |
| Phase 4 | NCT07426237 Comparator | Mar 2026 → Jul 2027 expected | — | Hospital Nossa Senhora da Conceicao | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06993038 Comparator | Aug 2025 → Jul 2027 expected | cardiac rhythm disease | Anne E. Zepeski | Recruiting | No outcome recorded |
| Phase 4 | NCT06578234 Comparator | Oct 2024 → Dec 2026 expected | coronary artery disorder, ischemic disease | Region Skane | Recruiting | No outcome recorded |
| Phase 4 | NCT07456423 Comparator | Jul 2024 → Jun 2025 | atrioventricular node disorder, cardiac rhythm disease | Haseki Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT04699110 Comparator | Jan → Apr 2021 | acute coronary syndrome | National Institute of Cardiovascular Diseases, Pakistan | Completed | Mixed |
| Phase 4 | NCT04666454 Comparator | Dec 2020 → Dec 2028 expected | Tako-tsubo cardiomyopathy | Vastra Gotaland Region | Recruiting | No outcome recorded |
| Phase 4 | NCT03249272 Comparator | Sep 2017 → Mar 2019 | coronary microvascular disorder, dilated cardiomyopathy, hypertrophic cardiomyopathy | Duke University | Terminated | No outcome recorded Stop: Business |
| — | NCT06854458 Background | Jun 2025 → Jan 2029 expected | ischemic disease | Brigham and Women's Hospital | Recruiting | No outcome recorded |
| — | NCT05471687 Background | Sep 2022 → Sep 2024 | coronary stenosis, diabetes mellitus | Hospices Civils de Lyon | Unknown | No outcome recorded |
| — | NCT04577443 Comparator | Nov 2020 → Oct 2021 | migraine disorder | Danish Headache Center | Completed | No outcome recorded |
| — | NCT04203368 Comparator | Feb → Jul 2020 | — | Ain Shams University | Completed | No outcome recorded |
| — | NCT03537586 Background | Jun 2018 → Jun 2025 overdue | coronary microvascular disorder, myocardial ischemia | NYU Langone Health | Active not recruiting | No outcome recorded |
| — | NCT04646278 Background | Apr 2017 → Mar 2020 | coronary artery disorder | KangWon National University Hospital | Completed | No outcome recorded |
| — | NCT03327168 Comparator | Nov 2015 → Jun 2016 | obesity disorder | Turku University Hospital | Completed | No outcome recorded |
| — | NCT02608944 Background | Sep 2012 → Jun 2019 | — | University of Utah | Withdrawn | No outcome recorded |
| — | NCT01370265 Comparator | Feb 2011 → Feb 2012 | coronary artery disorder | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00923962 Comparator | Jun 2009 → Jan 2012 | type 2 diabetes mellitus | University Hospital, Gentofte, Copenhagen | Completed | No outcome recorded |
| — | NCT00712764 Comparator | Jan → Apr 2005 | microvenular haemangioma, neuroocular syndrome | Medical University of Vienna | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2006-02-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Tentative Approval of Adenosine Injection tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted tentative approval for the Company's ANDA for Adenosine Injection, 3 mg/mL in 20 mL and 30 mL single dose vials. |
| 2004-06-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval Of Adenosine Injection tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq:TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Adenosine Injection USP, 3 mg/mL,which was submitted by the Company's subsidiary SICOR Inc. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-09-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Exclusive Launch of Generic ADENOSCAN® in the United States tevapharm.com ↗ |
| 2007-10-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Adenoscan® Patent Lawsuits Settled tevapharm.com ↗ |
| 2006-02-13 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Tentative Approval of Adenosine Injection tevapharm.com ↗ |
| 2005-05-27 | Astellas Pharma Inc | Astellas US LLC and Astellas Pharma US, Inc. Filed Lawsuit against Adenoscan Generic for Patent Infringement in the USA astellas.com ↗ |
| 2004-06-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Adenosine Injection tevapharm.com ↗ |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 78 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adenosine | “Adenosine is an endogenous purine nucleoside with pleiotropic cardioprotective properties, including negative chronotropic and dromotropic effects, coronary vasodilation,...” NCT07426237 ↗74“Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson.” NCT03354273 ↗ “Baseline angiography is performed without any stimulation and hyperemic angiography is performed after intracoronary injection of adenosine 300ug or nicorandiol 2mg.” NCT04646278 ↗ “Intracoronary bolus of at least 200 mcg of nitroprussiate or 500 mcg of intracoronary adenosine during 2 minutes.” NCT04685941 ↗ “All participants will receive vasodilator (regadenoson or adenosine depending on local site practice).” NCT06854458 ↗ “* Adenosine : administered intravenously during MRI for the measurement of CFR.” NCT04744636 ↗ “IV infusion of adenosine at a rate of 140 μg/kg/min.” NCT05885841 ↗ “IV infusion of adenosine at a rate of 140 μg/kg/min.” NCT07187895 ↗ “Adenosine” NCT03344679 ↗ |
| Known as | 9-.beta.-d-ribofuranosyladenine | ChEMBL registry synonym — accepted as the source's own label CHEMBL477 ↗ |
| Known as | Adenocard | “Other Names: Adenocard (if needed for registry consistency)” NCT07536802 ↗ |
| Known as | Adenocor | ChEMBL registry synonym — accepted as the source's own label CHEMBL477 ↗ |
| Known as | Adenoscan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01482169 ↗ |
| Known as | Adenoscan(adenosine) | “Adenoscan(adenosine)” NCT01161121 ↗ |
| Known as | adenosin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05471687 ↗ |
| Known as | NSC-7652 | ChEMBL registry synonym — accepted as the source's own label CHEMBL477 ↗ |
| Known as | SR 96225 | ChEMBL registry synonym — accepted as the source's own label CHEMBL477 ↗ |
| Action | Inhibit | “Adenosine may inhibit intrinsic neurons” NCT00298636 ↗ |
| Modality | Small molecule | “Adenosine is a nucleoside” NCT04577443 ↗ |
| Route | Other | “Adenosine intrarterial (intrabrachial) infusion” NCT00179010 ↗ |